title: [Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome].
abstract: OBJECTIVE
  To potentiate the effect of basic therapy and to correct of immune dysfunction in type 2 diabetes mellitus (T2DM) patients with diabetic foot syndrome by using the immunoregulatory peptide imunofan.
  
  
  METHODS
  Sixty-nine T2DM patients with the diabetic foot and retinal angiopathy were examined. All the patients were randomized to 2 groups: study (n = 39) and control (n = 30) groups matched for clinical manifestations, age, gender, and the duration and severity of the disease. The study group patients received basic therapy in accordance with the existing recommendations, as well as immunomodulation with imunofan; the control group had basic therapy only.
  
  
  RESULTS
  All the examinees were observed to have an android type of obesity; the detected immunological abnormalities largely involved cell-mediated immunity impairments. In the study group, therapeutic effectiveness was higher than that in the controls. Combined treatment reduced the magnitude of insulin resistance, caused positive clinical and laboratory parameters, and improved quality of life.
  
  
  CONCLUSIONS
  The regulatory peptide significantly normalizes cellular and humoral immunity improves quality of life, therefore it is expedient to use it in patients with T2DM.
authors.forename: A V
authors.initials: AV
authors.lastname: Tutel'ian
authors.forename: I A
authors.initials: IA
authors.lastname: Iakubovskaia
authors.forename: N V
authors.initials: NV
authors.lastname: Skrypnik
authors.forename: V V
authors.initials: VV
authors.lastname: Levedev
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D016207:Cytokines / Q000097:blood / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D017719:Diabetic Foot / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D056724:Immunity, Humoral / Q000187:drug effects; D007333:Insulin Resistance / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D007004:Hypoglycemic Agents; D009842:Oligopeptides; C080035:thymohexin